» Articles » PMID: 33598151

Safety Evaluation of High-dose Intake of Casein-derived Peptide Met-Lys-Pro in Healthy Adults: A Randomized, Double-blind, Placebo-controlled Trial

Overview
Journal Food Sci Nutr
Specialty Biotechnology
Date 2021 Feb 18
PMID 33598151
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Met-Lys-Pro (MKP) is a casein-derived angiotensin I-converting enzyme inhibitory peptide with the potential to cross the blood-brain barrier. It has shown preventive effects against high blood pressure (BP) and cognitive decline in animal models and human studies. MKP shows good water solubility and can be blended into a variety of foods. However, its ease of intake may contribute to the possibility of overdose. Therefore, we aimed to evaluate the safety of high-dose intake of MKP in healthy adults by conducting a randomized controlled trial with 30 subjects. Participants were randomly allocated to the MKP ( = 15) or placebo ( = 15) group. Over 4 weeks, the MKP group received test powder containing a daily dose of 1,000 μg of MKP, five times the minimum effective dose for cognitive improvement, whereas the placebo group received dextrin powder containing no detectable MKP. No clinical problems were observed in anthropometric and BP measurements or in blood and urine parameters. No adverse events owing to MKP intake were observed. These findings suggest that consumption of MKP is safe, and that it may be applicable as a safe preventive measure against hypertension and cognitive decline in future.

Citing Articles

Effects of Casein-Derived Peptide Met-Lys-Pro on Systolic and Diastolic Blood Pressure: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.

Sato S, Ochi D, Nabeshima K, Sakiyama R, Somoto Y, Nakano M Nutrients. 2024; 16(17).

PMID: 39275290 PMC: 11397617. DOI: 10.3390/nu16172975.


Safety evaluation of high-dose intake of casein-derived peptide Met-Lys-Pro in healthy adults: A randomized, double-blind, placebo-controlled trial.

Yuda N, Tanaka M, Tokushima M, Abe F Food Sci Nutr. 2021; 9(2):662-671.

PMID: 33598151 PMC: 7866589. DOI: 10.1002/fsn3.2028.

References
1.
Solfrizzi V, Panza F, Frisardi V, Seripa D, Logroscino G, Imbimbo B . Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert Rev Neurother. 2011; 11(5):677-708. DOI: 10.1586/ern.11.56. View

2.
Yamada A, Sakurai T, Ochi D, Mitsuyama E, Yamauchi K, Abe F . Antihypertensive effect of the bovine casein-derived peptide Met-Lys-Pro. Food Chem. 2014; 172:441-6. DOI: 10.1016/j.foodchem.2014.09.098. View

3.
Crous-Bou M, Minguillon C, Gramunt N, Molinuevo J . Alzheimer's disease prevention: from risk factors to early intervention. Alzheimers Res Ther. 2017; 9(1):71. PMC: 5596480. DOI: 10.1186/s13195-017-0297-z. View

4.
Zhang Y, Chen J, Qiu J, Li Y, Wang J, Jiao J . Intakes of fish and polyunsaturated fatty acids and mild-to-severe cognitive impairment risks: a dose-response meta-analysis of 21 cohort studies. Am J Clin Nutr. 2016; 103(2):330-40. DOI: 10.3945/ajcn.115.124081. View

5.
Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C . Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging. 2001; 22(4):541-6. DOI: 10.1016/s0197-4580(00)00259-1. View